© 2020 MJH Life Sciences and HCPLive. All rights reserved.
© 2020 MJH Life Sciences™ and HCPLive. All rights reserved.
September 25, 2020
Testing all IBD patients for CMV can lead to a concerning overconsumption of resources as well as a delay in treatment.
Dr. Yuen discusses some new treatments in the pipeline and how personalized medicine could make an impact in HBV treatment.
September 24, 2020
The trial was called off because of futility of the toxoid vaccine candidate.
September 23, 2020
The cut points for LCT and nCD64 in Crohn’s disease were not previously known.
Fecal material transplantation for the management of patients with IBD demonstrates a response rate of 53.8% with a complete remission of 37%.
September 20, 2020
This article is the third in a series of four articles exploring the epidemic of liver disease called nonalcoholic fatty liver disease and its more severe form, nonalcoholic steatohepatitis.
September 18, 2020
Ustekinumab should be prescribed cautiously to those at high cardiovascular risk.
September 16, 2020
Low levels of COC associated with a higher likelihood of outpatient flares that required corticosteroids, hospitalizations, and surgical interventions.
September 14, 2020
There are currently no FDA-approved treatments for eosinophilic esophagitis.
September 13, 2020
This article is the second in a series of four articles exploring the epidemic of liver disease called nonalcoholic fatty liver disease and its more severe form, nonalcoholic steatohepatitis.